SARS-CoV-2 and myasthenia

J Med Virol. 2021 Jul;93(7):4133-4135. doi: 10.1002/jmv.26501. Epub 2021 Jan 28.

Authors

Josef Finsterer¹, Fulvio A Scorza², Carla A Scorza², Ana C Fiorini³

Affiliations

¹ Klinik Landstrasse, Messerli Institute, Vienna, Austria.
² Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brasil.
³ Departamento de Fonoaudiologia, Programa de Estudos Pós-Graduado em Fonoaudiologia, Pontifícia Universidade Católica de São Paulo (PUC-SP), Escola Paulista de Medicina/Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil.

PMID: 32910499
DOI: 10.1002/jmv.26501

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Viral / immunology*
COVID-19 / pathology*
Cross Reactions / immunology
Epitopes / immunology
Female
Humans
Immunocompromised Host / physiology
Male
Middle Aged
Muscular Diseases / genetics
Muscular Diseases / immunology
Myasthenia Gravis / drug therapy
Myasthenia Gravis / epidemiology*
Myasthenia Gravis / pathology
Receptors, Cholinergic / immunology*
SARS-CoV-2

Substances

Antibodies, Viral
Epitopes
Receptors, Cholinergic